iHealthScreen offers a fully automated AI-based screening tool for detecting diabetic retinopathy, age-related macular degeneration, and glaucoma in primary care settings. This technology provides rapid, non-invasive retinal imaging analysis, enabling timely diagnosis and referral to prevent vision loss in at-risk populations.
Funding
$320K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
In primary care settings, the detection of progressive retinal diseases like diabetic retinopathy, age-related macular degeneration, and glaucoma often relies on specialized equipment and expert interpretation, leading to delayed diagnoses and potential vision loss. The limited availability of retinal specialists and variability in image interpretation further exacerbate this issue.
Solution
iHealthScreen offers iPredict, an AI-powered screening tool designed for use in primary care that enables non-specialists to screen patients for AMD, DR and Glaucoma. The iPredict system uses automated fundus cameras to capture retinal images, which are then securely transmitted to a centralized server. iPredict's AI/ML algorithms analyze these images, classifying patients as referable or non-referable for AMD, DR and Glaucoma and quantifying an individual's risk of developing late-stage disease within one or two years. By providing rapid, accurate risk assessments, iHealthScreen facilitates timely referrals to ophthalmologists, enabling earlier intervention and potentially preventing vision loss.
Target Audience
The primary target audience includes primary care physicians and other healthcare providers who need a rapid, accurate, and easy-to-use tool for screening patients for retinal diseases during routine checkups.
Features
- AI-based analysis of retinal images for signs of diabetic retinopathy, age-related macular degeneration, and glaucoma
- Automated classification of patients as referable or non-referable, streamlining the referral process
- Prediction score quantifying an individual's risk of developing late-stage AMD within one or two years
- Integration with fully automated fundus cameras for image capture in primary care settings
- Secure data transmission to a centralized server for analysis
- Rapid report generation, providing results in under a minute
- Prospective validation of screening model, with submission to the FDA